← Leaderboards
Ruth A Keri
Cleveland Clinic Lerner Com-Cwru
$12,224,731
Attributed
$12,224,731
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,224,731 · 8
By mechanism
R01$11,380,828 · 6
R21$843,903 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsTumorMalignant NeoplasmsMalignant Breast NeoplasmBreast Cancer CellResponseNeoplastic CellProteinsErbb2 GeneResistanceMediatingSignal TransductionIn VitroGrowthTranscription FactorIn VivoCellsTumor ProgressionMouse ModelInsightTherapeutic TargetFamilyTriple-Negative Invasive Breast CarcinomaReceptor
Grant awards (46)
Discovering the role of YES1 in triple negative breast cancer$461,334
R01 · FY2025 · CA · contact PI
Targeting NEK2 to potentiate standard of care therapies for breast cancer$225,803
R21 · FY2025 · CA · contact PI
Discovering the role of YES1 in triple negative breast cancer$71,136
R01 · FY2025 · CA · contact PI
Discovering the role of YES1 in triple negative breast cancer$438,269
R01 · FY2024 · CA · contact PI
Supplement - Discovering the role of YES1 in triple negative breast cancer$365,768
R01 · FY2024 · CA · contact PI
Targeting NEK2 to potentiate standard of care therapies for breast cancer$188,169
R21 · FY2024 · CA · contact PI
Discovering the role of YES1 in triple negative breast cancer$71,850
R01 · FY2024 · CA · contact PI
Discovering the role of YES1 in triple negative breast cancer$452,109
R01 · FY2023 · CA · contact PI
Discovering the role of YES1 in triple negative breast cancer$31,315
R01 · FY2023 · CA · contact PI
Discovering the role of YES1 in triple negative breast cancer$452,109
R01 · FY2022 · CA · contact PI
Discovering the role of YES1 in triple negative breast cancer$461,334
R01 · FY2021 · CA · contact PI
Elucidating and Leveraging the mTOR Negative Feedback Pathway in Breast Cancer$410,801
R01 · FY2021 · CA · contact PI
Elucidating and Leveraging the mTOR Negative Feedback Pathway in Breast Cancer$304,945
R01 · FY2020 · CA · contact PI
Targeting BET proteins in Triple Negative Breast Cancer$209,273
R01 · FY2020 · CA · contact PI
Targeting BET proteins in Triple Negative Breast Cancer$157,640
R01 · FY2020 · CA · contact PI
Elucidating and Leveraging the mTOR Negative Feedback Pathway in Breast Cancer$105,856
R01 · FY2020 · CA · contact PI
Elucidating and Leveraging the mTOR Negative Feedback Pathway in Breast Cancer$396,207
R01 · FY2019 · CA · contact PI
Targeting BET proteins in Triple Negative Breast Cancer$355,907
R01 · FY2019 · CA · contact PI
Elucidating and Leveraging the mTOR Negative Feedback Pathway in Breast Cancer$408,250
R01 · FY2018 · CA · contact PI
Targeting BET proteins in Triple Negative Breast Cancer$366,913
R01 · FY2018 · CA · contact PI
Elucidating and Leveraging the mTOR Negative Feedback Pathway in Breast Cancer$408,250
R01 · FY2017 · CA · contact PI
Targeting BET proteins in Triple Negative Breast Cancer$366,913
R01 · FY2017 · CA · contact PI
Targeting BET proteins in Triple Negative Breast Cancer$373,968
R01 · FY2016 · CA · contact PI
KLF4 regulation of epithelial/mesenchymal transition in breast cancer$325,775
R01 · FY2015 · CA · contact PI
A novel regulator of breast development$231,806
R21 · FY2015 · HD · contact PI
KLF4 regulation of epithelial/mesenchymal transition in breast cancer$316,002
R01 · FY2014 · CA · contact PI
A novel regulator of breast development$198,125
R21 · FY2014 · HD · contact PI
KLF4 regulation of epithelial/mesenchymal transition in breast cancer$306,229
R01 · FY2013 · CA · contact PI
KLF4 regulation of epithelial/mesenchymal transition in breast cancer$325,775
R01 · FY2012 · CA · contact PI
KLF4 regulation of epithelial/mesenchymal transition in breast cancer$325,775
R01 · FY2011 · CA · contact PI
Regulation of erbB2/Neu-induced mammary gland cancer$204,878
R01 · FY2011 · CA · contact PI
Regulation of erbB2/Neu-induced mammary gland cancer$211,288
R01 · FY2010 · CA · contact PI
Regulation of erbB2/Neu-induced mammary gland cancer$213,979
R01 · FY2009 · CA · contact PI
Regulation of erbB2/Neu-induced mammary gland cancer$86,339
R01 · FY2009 · CA · contact PI
Mammary cancer suceptibility following in utero exposure to bisphenol A$227,115
R01 · FY2008 · ES · contact PI
Regulation of erbB2/Neu-induced mammary gland cancer$212,114
R01 · FY2008 · CA · contact PI
Regulation of erbB2/Neu-induced mammary gland cancer$77,462
R01 · FY2008 · CA · contact PI
Regulation of erbB2/Neu-induced mammary gland cancer$216,920
R01 · FY2007 · CA · contact PI
Mammary cancer suceptibility following in utero exposure to bisphenol A$193,125
R01 · FY2007 · ES · contact PI
Regulation of erbB2 induced mammary gland cancer$221,600
R01 · FY2005 · CA
Regulation of erbB2 induced mammary gland cancer$48,397
R01 · FY2005 · CA
Regulation of erbB2 induced mammary gland cancer$387,156
R01 · FY2004 · CA
Regulation of erbB2 induced mammary gland cancer$25,545
R01 · FY2004 · CA
Regulation of erbB2 induced mammary gland cancer$372,107
R01 · FY2003 · CA
Regulation of erbB2 induced mammary gland cancer$206,550
R01 · FY2002 · CA
Regulation of erbB2 induced mammary gland cancer$206,550
R01 · FY2001 · CA